In vitro data showed how Midostaurin resistance can be overcome by a combination of Midostaurin, the BCL-2 inhibitor Venetoclax, and the RAC1 inhibitor Eht1864, in FLT3-ITDmut AML cell lines and primary samples. Here, BCL2 is linked to acute myeloid leukemia.